Breaking Ground: AI-Powered Innovations in Drug Development

The next significant breakthrough for artificial intelligence in healthcare is shifting from laboratory research to real-world clinical trials — where the success or failure of new drugs is determined.

For years, discussions about AI in healthcare focused mainly on the early stages: drug discovery. The industry celebrated algorithms that could predict protein structures and identify new molecules. However, at the recent J.P. Morgan Healthcare Conference held in San Francisco, it became clear that attention is finally turning toward what many see as the “final frontier” — clinical trials.

As we progress into 2026 and beyond, the industry faces a “Dual Exponential Growth” challenge that will shape the future of healthcare.

Leveraging Moore’s Law to Overcome Eroom’s Law

The tech sector draws much of its power from Moore’s Law — the trend of exponentially increasing computing power and decreasing costs roughly every two years. Today’s computers are about 1,000 times more powerful than those a decade ago and nearly a million times more capable than those from two decades ago. This rapid growth has enabled the software industry to “disrupt” nearly every sector.

In contrast, the healthcare and drug development industries operate under Eroom’s Law — the reverse of Moore’s Law. These fields have faced decades of rising costs, now reaching unsustainable levels, with healthcare spending in the U.S. nearing a quarter of the GDP. Rising expenses for labor, administration, and clinical trials are driving therapeutics along an increasing cost curve.

The real cost to develop a new drug today, adjusted for inflation, doubles approximately every nine years. To reverse this trend, the industry must shift from Eroom’s Law to Moore’s Law by transforming human-driven processes into computational systems — essentially turning complex clinical services into technology-enabled, commoditized operations.

Oncology: The Testing Ground for AI Innovation

Cancer treatment remains the clearest example of this transformation. It accounts for about one-third of AI collaborations among leading pharma companies. The vast amount of high-quality data and the biological complexity of cancer make oncology an ideal testing ground for AI applications.

At this year’s conference, this momentum shifted from conceptual ideas to large-scale initiatives. A notable announcement involved a $1 billion partnership between Nvidia and Eli Lilly, aiming to develop a “continuous learning” system that seamlessly connects laboratory experimentation with computational analysis around the clock.

This follows a wave of significant investments made in 2025, including:

• AstraZeneca’s over $1 billion partnership with BenevolentAI focused on AI-driven immunotherapy.
• Bristol Myers Squibb’s more than $80 million collaboration with Owkin to identify novel targets in immuno-oncology.
• Roche/Genentech’s over $150 million deal with Recursion Pharmaceuticals to accelerate antibody discovery.

Breaking the Bottleneck in Clinical Development

The pharmaceutical industry struggles with about a 90% failure rate for drugs entering clinical trials. Since research and development costs can account for up to 70% of total expenses due to project failures, improving this stage is a top priority for AI solutions.

One of the most exciting developments heading into 2026 is the rise of autonomous AI agents. A new “Moore’s Law for AI agents” has emerged: the ability of AI systems to perform tasks independently doubles approximately every seven months. While early AI models handled only short, simple tasks, today’s agents can manage multi-hour, complex professional projects.

Innovators are deploying specialized tools to address the “complex middle” of drug development, including:

• The rise of AI agents: Tools like Medable’s “TMF Agent” automate labor-intensive trial documentation processes.
• Dedicated AI collaborators: Firms such as HopeAI showcase how “AI clinicians” and “AI statisticians” can optimize trial design and improve regulatory outcomes through biostatistics modeling.
• Reliable evidence sources: Platforms like Pure Evidence supply human-curated, high-quality clinical databases to ensure data integrity and timeliness.
• Operational streamlining: Sanofi applies AI to streamline patient recruitment, and companies like Merck and Pfizer use generative AI to optimize clinical records and regulatory documentation.

The Ecosystem of Collaboration and Global Connectivity

Progress increasingly depends on deep collaboration between biotech firms, specialized technology providers, and major hospital systems such as Mass General Brigham. Isolated internal efforts are limited by fragmented data access; advanced algorithms perform best when trained on diverse, broad datasets from multiple sources.

In the global arena, AI is also strengthening the connection between China and the rest of the world. Chinese companies like RemeGen — which recently signed a licensing agreement worth $5.6 billion with AbbVie — combine robust local clinical pipelines with AI-powered evidence platforms that meet international standards.

Looking Ahead: Trends for 2026 and Beyond

The era of “AI disillusionment” appears to be ending, as the industry applies the right tools to the most pressing challenges. Evidence of progress is increasing in key indicators:

• Approval success rates: AI-discovered drugs are now achieving Phase I success rates of 80–90%, nearly doubling traditional rates.
• Pipeline growth: Over 3,000 AI-assisted drug candidates are currently in development.
• Future approvals: More than 200 AI-enabled drugs are expected to receive approval by 2030.

To thrive in this environment, organizations need to enhance data governance and foster a workforce that views AI as a core driving force. The goal is to turn the path from laboratory to patient into a smooth, efficient highway powered by intelligent, evidence-based systems.